Participant experiences in a combination HIV cure-related trial with extended analytical treatment interruption in San Francisco, United States

References

• Deeks SG, Archin N, Cannon P, et al. Research priorities for an HIV cure: International AIDS society global scientific strategy 2021. Nat Med. 2021;27(12):2085–2098. Available from: https://www.nature.com/articles/s41591-021-01590-5
   PubMed Web of Science ®Google Scholar
• TAG. Research toward a cure trials. 2023. Available from: http://www.treatmentactiongroup.org/cure/trials.
   Google Scholar
• Dubé K, Kanazawa J, Louella M, et al. Considerations for designing and implementing combination HIV cure trials: Findings from a qualitative in-depth interview study in the United States. AIDS Res Ther. 2021;28(75):1–17. Available from:
   Google Scholar
• Ananworanich J, Barré-Sinoussi F. Is it time to abandon single intervention cure trials? Lancet HIV. 2015;2(10):e410–e411. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26423646
   PubMed Web of Science ®Google Scholar
• Hurst J, Hoffmann M, Pace M, et al. Immunological biomarkers predict HIV-1 viral rebound after treatment interruption. Nat Commun. 2015;6(1):8495. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4633715&tool=pmcentrez&rendertype=abstract
   PubMedGoogle Scholar
• Peluso MJ, Dee L, Campbell D, et al. A collaborative, multidisciplinary approach to HIV transmission risk mitigation during analytic treatment interruption. J Virus Erad. 2020;6(1):34–37.
   PubMed Web of Science ®Google Scholar
• Dubé K, Kanazawa JT, Dee L, et al. Ethical and practical considerations for mitigating risks to sexual partners during analytical treatment interruptions in HIV cure-related research. HIV Res Clin Pract. 2021;24:1–17.
   Google Scholar
• Dubé K, Morton T, Fox L, et al. A partner protection package for HIV cure-related trials involving analytical treatment interruptions. Lancet Infect Dis. 2023;23(10):e418–e430. Available from:
   PubMed Web of Science ®Google Scholar
• Lo B, Grady C. Ethical considerations in HIV cure research: Points to consider. Curr Opin HIV AIDS. 2013;8(3):243–249. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23422260
   PubMed Web of Science ®Google Scholar
• Garner SA, Rennie S, Ananworanich J, et al. Interrupting antiretroviral treatment in HIV cure research: Scientific and ethical considerations. J Virus Erad. 2017;3(2):82–84.
   PubMed Web of Science ®Google Scholar
• Julg B, Dee L, Ananworanich J, et al. Recommendations for analytical treatment interruptions in HIV research trials. Report of a consensus meeting. Lancet HIV. 2019;6(4):e259-68–e268.
   Web of Science ®Google Scholar
• Eyal N, Holtzman LG, Deeks SG. Ethical issues in HIV remission trials. Curr Opin HIV AIDS. 2018;13(5):422–427.
   PubMed Web of Science ®Google Scholar
• Dubé K, Kanazawa J, Taylor J, et al. Ethics of HIV cure research: an unfinished agenda. BMC Med Ethics. 2021;22(1):83. Available from:
   PubMed Web of Science ®Google Scholar
• Dubé K, Hosey L, Starr K, et al. Participant perspectives in an HIV cure-related trial conducted exclusively in women in the United States: Results from AIDS clinical trials group (ACTG) 5366. AIDS Res Hum Retroviruses. 2020;36(4):268–282.
   PubMed Web of Science ®Google Scholar
• Diepstra KL, Barr L, Palm D, et al. Participant perspectives and experiences entering an intensively monitored antiretroviral pause: Results from the AIDS clinical trials group A5345 biomarker study. AIDS Res Hum Retroviruses. 2021;37(6):489–501.
   PubMed Web of Science ®Google Scholar
• Dubé K, Eskaf S, Barr L, et al. Participant perspectives and experiences following an intensively monitored antiretroviral pause in the United States: Results from the AIDS clinical trials group A5345 biomarker study. AIDS Res Hum Retroviruses. 2022;38(6):510–517.
   PubMed Web of Science ®Google Scholar
• Neergaard R, Jones NL, Roebuck C, et al. “I know that I was a part of making a difference”: participant motivations for joining a cure-Directed HIV trial with an analytical treatment interruption. AIDS Res Hum Retroviruses. 2022;39(8):414–421.
   PubMed Web of Science ®Google Scholar
• Perry KE, Dubé K, Concha-Garcia S, et al. My death will not [be] in vain: Testimonials from last gift rapid research study participants living with HIV at the end of life. AIDS Res Hum Retroviruses. 2020;36(12):1071–1082.
   PubMed Web of Science ®Google Scholar
• De Scheerder M, Bilsen WV, Dullaers M, et al. Motivations, barriers and experiences of participants in an HIV reservoir trial. J Virus Erad. 2021;7(1):100029.
   PubMed Web of Science ®Google Scholar
• Henderson GE, Waltz M, Meagher K, et al. Going off antiretroviral treatment in a closely monitored HIV “cure” trial: Longitudinal assessments of acutely diagnosed trial participants and decliners. J Int. 2019;22:e25260.
   Web of Science ®Google Scholar
• Peluso MJ, Dee L, Shao S, et al. Operationalizing HIV cure-related trials with analytic treatment interruptions during the SARS-Cov-2 pandemic: a collaborative approach. Clin Infect Dis. 2021;72(10):1843–1849.
   PubMed Web of Science ®Google Scholar
• Peluso MJ, Dee L, Taylor J, et al. SARS-Cov-2 vaccination in the context of ongoing HIV cure-related studies. J Acquir Immune Defic Syndr. 2021;87(4):e232-3–e233.
   Web of Science ®Google Scholar
• Peluso M, Williams M, Campbell D, et al. SARS-Cov-2 booster vaccination for participants in “HIV cure”-related clinical trials. J Acquir Immune Defic Syndr. 2022;89(3):e30–e30.
   PubMed Web of Science ®Google Scholar
• Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277–1288.
   PubMed Web of Science ®Google Scholar
• Peluso M, Deitchman A, Magombedze G, et al. Rebound dynamics following immunotherapy with an HIV vaccine, TLR-9 agonist, and bNAbs. In: Conference on Retroviruses and Opportunistic Infections (CROI); 2023.
   Google Scholar
• Gilbertson A, Kelly EP, Rennie S, et al. Indirect benefits in HIV cure clinical research: a qualitative analysis. AIDS Res Hum Retroviruses. 2019;35(1):100–107.
   PubMed Web of Science ®Google Scholar
• Henderson GE, Peay HL, Kroon E, et al. Ethics of treatment interruption trials in HIV cure research: Addressing the conundrum of risk/benefit assessment. J Med Ethics. 2018;44(4):270–276.
   PubMed Web of Science ®Google Scholar
• Arnold M, Evans D, Vergel N. Recruitment and ethical considerations in HIV cure trials requiring treatment interruption. J Virus Erad. 2015;1(1):43–48.
   PubMedGoogle Scholar
• Evans D. An activist’s argument that participant values should guide risk–benefit ratio calculations in HIV cure research. J Med Ethics. 2017;43(2):100–103. Available from: 10.1136/medethics-2015-103120
   PubMed Web of Science ®Google Scholar
• Dubé K, Perry K, Mathur K, et al. Altruism: scoping review of the literature and future directions for HIV cure-related research. J Virus Erad. 2020;6(4):100008.
   PubMed Web of Science ®Google Scholar
• Dubé K, Taylor J, Sylla L, et al. Well, it’s the risk of the unknown … right ?’: a qualitative study of perceived risks and benefits of HIV cure research in the United States. PLoS One. 2017;12(1):e0170112.
   PubMed Web of Science ®Google Scholar
• Lantos J. The “inclusion benefit” in clinical trials. J Pediatr. 1999;134(2):130–131. ():
   PubMed Web of Science ®Google Scholar
• Dubé K, Ramirez C, Handibode J, et al. Participation in HIV cure-related research: a scoping review of the proxy literature and implications for future research. J Virus Erad. 2015;1:e14-20.
   Google Scholar
• Bilger A, Plenn E, Barg FK, et al. Participant experiences in HIV cure-Directed trial with an extended analytical treatment interruption in Philadelphia, United States. HIV Res Clin Pract. 2023;24(1):2267825.
   PubMed Web of Science ®Google Scholar
• Dubé K, Dee L, Evans D, et al. Perceptions of equipoise, risk–benefit ratios, and “otherwise healthy volunteers” in the context of early-Phase HIV cure research in the United States: a qualitative inquiry. J Empirical Res Hum Res Ethics. 2018;13(1):3–17.
   PubMed Web of Science ®Google Scholar
• Henderson GE. The ethics of HIV “cure” research: What can We learn from consent forms? AIDS Res Hum Retroviruses. 2014;31(1):1–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25406579%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4287120
   Web of Science ®Google Scholar
• Annas GJ. Cure research and consent: the Mississippi baby, Barney Clark, baby Fae, and Martin Delaney. J Med Ethics. 2017;43(2):104–107.
   PubMed Web of Science ®Google Scholar
• Peay H, Henderson G. What motivates participation in HIV cure trials? A call for real-time assessment to improve informed consent. J Virus Erad. 2015;1(1):51–53.
   PubMedGoogle Scholar
• Perrault T. POZ. 2022 [cited 2023 Sep 1]. My HIV Cure Trial. Available from: https://www.poz.com/article/hiv-cure-trial.
   Google Scholar
• Horng S, Grady C. Misunderstanding in clinical research: Distinguishing therapeutic misconception, therapeutic misestimation, and therapeutic optimism. IRB. 2003;25(1):11–16.
   PubMedGoogle Scholar
• Campbell D, Dubé K, Cowlings P, et al. “It comes altogether as one”: perceptions of analytical treatment interruptions and partner protections among racial, ethnic, sex and gender diverse HIV serodifferent couples in the United States. BMC Public Health. 2022;22(1):1317.
   PubMed Web of Science ®Google Scholar
• Dubé K, Agarwal H, Stockman JK, et al. “I would absolutely need to know that my partner is still going to be protected”: perceptions of HIV cure-related research among diverse HIV serodifferent couples in the United States. AIDS Res Hum Retroviruses. 2022;39(8):400–413.
   PubMed Web of Science ®Google Scholar
• Dubé K, Evans D, Dee L, et al. “We need to deploy them very thoughtfully and carefully”: perceptions of analytical treatment interruptions in HIV cure. AIDS Res Hum Retroviruses. 2018;34(1):67–79.
   PubMed Web of Science ®Google Scholar
• Power J, Westle A, Dowsett GW, et al. Perceptions of HIV cure research among people living with HIV in Australia. PLoS One. 2018;13(8):e0202647. Available from:
   PubMed Web of Science ®Google Scholar
• Lau JSY, Smith MZ, Allan B, et al. Perspectives on analytical treatment interruptions in people living with HIV and their health care providers in the landscape of HIV cure-focused studies. AIDS Res Hum Retroviruses. 2019;36(4):260–267.
   PubMed Web of Science ®Google Scholar
• Dubé K, Kanazawa JT, Campbell C, et al. Considerations for increasing racial, ethnic, gender and sexual diversity in HIV cure-related research with analytical treatment interruptions: a qualitative inquiry. AIDS Res Hum Retroviruses. 2022;38(1):50–63.
   PubMed Web of Science ®Google Scholar
• Dubé K, Barr E, Philbin M, et al. Increasing the meaningful involvement of women in HIV cure-related research: a qualitative interview study in the United States. HIV Res Clin Pract. 2023;24(1):2246717. Available from:
   PubMed Web of Science ®Google Scholar
• Dubé K, Mthimkhulu D, Ngcobo W, et al. “With this study, we have hope that something is coming”: community members’ perceptions of HIV cure-related research in durban, South Africa - a qualitative focus group study. HIV Res Clin Pract. 2023;24(1):1–13.
   Google Scholar
• Miall A, McLellan R, Dong K, et al. Bringing social context into global biomedical HIV cure-related research: an urgent call to action. J Virus Erad. 2022;8(1):8–10.
   Web of Science ®Google Scholar
• Guest G, Bunce A, Johnson L. How many interviews are enough?: an experiment with data saturation and variability. Field Methods. 2006;18(1):59–82. Available from: 10.1177/1525822X05279903
   Web of Science ®Google Scholar